Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Obesity

Treatments: Drug: CP-741,952

Study type: Interventional

Funder types: Industry

Identifiers

NCT00367783

A7081004

Details and patient eligibility

About

The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.

Full description

Following review of the preliminary data from completed study A7081004, the development program for CP-741,952 was terminated on 15 March 2007. Primary reasons for program termination included a lack of significant efficacy at all doses investigated and an increased incidence of mild to moderate elevations in serum transaminases, primarily alanine aminotransferase (ALT), and liver fat content, in treated compared to placebo subjects. A synopsis will be created and will include greater detail on these findings.

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI of 30-40 kg/m2

Exclusion criteria

• Women of childbearing potential

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind